BUMN Vaccines Must Accelerate Pandemic Handling

Photo by Mufid Majnun on Unsplash

JAKARTA - The BUMN vaccine, which is now entering the third phase of clinical trials, is expected to contribute positively to increasing the coverage of COVID-19 vaccination in the country.

"If this vaccine has completed phase 3 clinical trials with good results, of course, it will greatly support the acceleration of vaccination and help accelerate the handling of the pandemic," said Chairman of the Indonesian Lung Doctors Association (PDPI) Dr. dr. Agus Dwi Susanto, Sp.P(K), when contacted, Saturday 11 June quoted from Antara.

Agus Dwi Susanto said the SOE vaccine shows that Indonesia has the ability to produce vaccines.

"However, COVID-19 vaccination is still one of the efforts needed to accelerate the handling of the pandemic," he said.

Doctor Agus added that with the development of BUMN vaccines, Indonesia would be able to become a world vaccine production hub.

"Innovations made by developing a COVID-19 vaccine in the country need to be appreciated, because it shows a very good step in developing technology in the health sector," he said.

In the future, he said, various innovations in the country, especially in the field of health technology, must continue to be improved.

Meanwhile, Head of the Professional Development Division of the Indonesian Association of Epidemiologists (PAEI) Masdalina Pane added that the BUMN vaccine, which is now entering the third phase of clinical trials, will increase the distribution of vaccines evenly.

"Hopefully, with the BUMN vaccine, access to vaccines will continue to increase and reach all targets, evenly to the ends of Indonesia," he said.

Meanwhile, as previously reported, the Indonesian Food and Drug Supervisory Agency (BPOM) issued a permit for the development of the final stage clinical trial for the BUMN Vaccine, which is a collaboration between PT Bio Farma, Baylor College of Medicine, and Eijkman.

"The development of the first BUMN Vaccine in Indonesia is the work of the nation's children in preclinical development until this last or third phase. We have given permission and have fulfilled the stages of good clinical trial methods," said Head of BPOM RI Penny K Lukito.

Penny said BPOM had assisted the development of BUMN Vaccines, from production facilities to the use of vaccines that had met the standard procedures for Good Manufacturing Practices (GMP) or good production methods according to regulations.